176 related articles for article (PubMed ID: 28373900)
1. Prevention of Streptozotocin-Induced Diabetic Nephropathy by MG132: Possible Roles of Nrf2 and I
Kong L; Wang Y; Luo M; Tan Y; Cui W; Miao L
Oxid Med Cell Longev; 2017; 2017():3671751. PubMed ID: 28373900
[TBL] [Abstract][Full Text] [Related]
2. Potential role for Nrf2 activation in the therapeutic effect of MG132 on diabetic nephropathy in OVE26 diabetic mice.
Cui W; Li B; Bai Y; Miao X; Chen Q; Sun W; Tan Y; Luo P; Zhang C; Zheng S; Epstein PN; Miao L; Cai L
Am J Physiol Endocrinol Metab; 2013 Jan; 304(1):E87-99. PubMed ID: 23132297
[TBL] [Abstract][Full Text] [Related]
3. Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome.
Luo ZF; Qi W; Feng B; Mu J; Zeng W; Guo YH; Pang Q; Ye ZL; Liu L; Yuan FH
Life Sci; 2011 Mar; 88(11-12):512-20. PubMed ID: 21241714
[TBL] [Abstract][Full Text] [Related]
4. Epigallocatechin gallate upregulates NRF2 to prevent diabetic nephropathy via disabling KEAP1.
Sun W; Liu X; Zhang H; Song Y; Li T; Liu X; Liu Y; Guo L; Wang F; Yang T; Guo W; Wu J; Jin H; Wu H
Free Radic Biol Med; 2017 Jul; 108():840-857. PubMed ID: 28457936
[TBL] [Abstract][Full Text] [Related]
5. SP600125 suppresses
Zhang H; Liu X; Zhou S; Jia Y; Li Y; Song Y; Wang J; Wu H
J Mol Endocrinol; 2018 Feb; 60(2):145-157. PubMed ID: 29273684
[TBL] [Abstract][Full Text] [Related]
6. Metallothionein plays a prominent role in the prevention of diabetic nephropathy by sulforaphane via up-regulation of Nrf2.
Wu H; Kong L; Cheng Y; Zhang Z; Wang Y; Luo M; Tan Y; Chen X; Miao L; Cai L
Free Radic Biol Med; 2015 Dec; 89():431-42. PubMed ID: 26415026
[TBL] [Abstract][Full Text] [Related]
7. Sulforaphane prevents type 2 diabetes-induced nephropathy via AMPK-mediated activation of lipid metabolic pathways and Nrf2 antioxidative function.
Li Z; Guo H; Li J; Ma T; Zhou S; Zhang Z; Miao L; Cai L
Clin Sci (Lond); 2020 Sep; 134(18):2469-2487. PubMed ID: 32940670
[TBL] [Abstract][Full Text] [Related]
8. C66 ameliorates diabetic nephropathy in mice by both upregulating NRF2 function via increase in miR-200a and inhibiting miR-21.
Wu H; Kong L; Tan Y; Epstein PN; Zeng J; Gu J; Liang G; Kong M; Chen X; Miao L; Cai L
Diabetologia; 2016 Jul; 59(7):1558-1568. PubMed ID: 27115417
[TBL] [Abstract][Full Text] [Related]
9. Sodium butyrate activates NRF2 to ameliorate diabetic nephropathy possibly via inhibition of HDAC.
Dong W; Jia Y; Liu X; Zhang H; Li T; Huang W; Chen X; Wang F; Sun W; Wu H
J Endocrinol; 2017 Jan; 232(1):71-83. PubMed ID: 27799462
[TBL] [Abstract][Full Text] [Related]
10. MDM2 controls NRF2 antioxidant activity in prevention of diabetic kidney disease.
Guo W; Tian D; Jia Y; Huang W; Jiang M; Wang J; Sun W; Wu H
Biochim Biophys Acta Mol Cell Res; 2018 Aug; 1865(8):1034-1045. PubMed ID: 29704532
[TBL] [Abstract][Full Text] [Related]
11. P53/NRF2 mediates SIRT1's protective effect on diabetic nephropathy.
Ma F; Wu J; Jiang Z; Huang W; Jia Y; Sun W; Wu H
Biochim Biophys Acta Mol Cell Res; 2019 Aug; 1866(8):1272-1281. PubMed ID: 30959066
[TBL] [Abstract][Full Text] [Related]
12. Prevention of diabetic nephropathy by sulforaphane: possible role of Nrf2 upregulation and activation.
Cui W; Bai Y; Miao X; Luo P; Chen Q; Tan Y; Rane MJ; Miao L; Cai L
Oxid Med Cell Longev; 2012; 2012():821936. PubMed ID: 23050040
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of Nrf2 is involved in FGF21-mediated fenofibrate protection against type 1 diabetic nephropathy.
Cheng Y; Zhang J; Guo W; Li F; Sun W; Chen J; Zhang C; Lu X; Tan Y; Feng W; Fu Y; Liu GC; Xu Z; Cai L
Free Radic Biol Med; 2016 Apr; 93():94-109. PubMed ID: 26849944
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-κB.
Wang Y; Sun W; Du B; Miao X; Bai Y; Xin Y; Tan Y; Cui W; Liu B; Cui T; Epstein PN; Fu Y; Cai L
Am J Physiol Heart Circ Physiol; 2013 Feb; 304(4):H567-78. PubMed ID: 23220333
[TBL] [Abstract][Full Text] [Related]
15. Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating Sirt1 to resist AGEs-induced upregulation of fibronetin and transforming growth factor-β1 in rat glomerular messangial cells.
Huang K; Chen C; Hao J; Huang J; Wang S; Liu P; Huang H
Mol Cell Endocrinol; 2015 Jan; 399():178-89. PubMed ID: 25192797
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy.
Zheng H; Whitman SA; Wu W; Wondrak GT; Wong PK; Fang D; Zhang DD
Diabetes; 2011 Nov; 60(11):3055-66. PubMed ID: 22025779
[TBL] [Abstract][Full Text] [Related]
17. The beneficial effects of zinc on diabetes-induced kidney damage in murine rodent model of type 1 diabetes mellitus.
Yang F; Li B; Dong X; Cui W; Luo P
J Trace Elem Med Biol; 2017 Jul; 42():1-10. PubMed ID: 28595780
[TBL] [Abstract][Full Text] [Related]
18. MG132 ameliorates kidney lesions by inhibiting the degradation of Smad7 in streptozotocin-induced diabetic nephropathy.
Gao C; Aqie K; Zhu J; Chen G; Xu L; Jiang L; Xu Y
J Diabetes Res; 2014; 2014():918396. PubMed ID: 24511554
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of digitoflavone on diabetic nephropathy: nuclear factor erythroid 2-related factor 2-dependent anti-oxidant and anti-inflammatory effect.
Yang Y; Chen G; Cheng X; Teng Z; Cai X; Yang J; Sun X; Lu W; Wang X; Yao Y; Hu C; Cao P
Sci Rep; 2015 Jul; 5():12377. PubMed ID: 26205695
[TBL] [Abstract][Full Text] [Related]
20. Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection.
Dreger H; Westphal K; Weller A; Baumann G; Stangl V; Meiners S; Stangl K
Cardiovasc Res; 2009 Jul; 83(2):354-61. PubMed ID: 19351736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
